insights_auto
Why is GXE up 2.33%?
Dive Deeperchevron_right
GXE:ETR
Lakefront Biotherapeutics NV
€26.36
arrow_upward
+2.33%(+0.60) 1D
Oct 9, 5:35:42 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GXE...
Open
€26.14
High
€26.36
Low
€26.14
Mkt. cap
1.69B
Avg. vol.
523.00
Volume
0.00
P/E ratio
2.91
52-wk high
€30.02
52-wk low
€22.84
EPS
€9.05
No. of employees
196
Open
€26.14
High
€26.36
Low
€26.14
Mkt. cap
1.69B
Avg. vol.
523.00
Volume
0.00
P/E ratio
2.91
52-wk high
€30.02
52-wk low
€22.84
EPS
€9.05
No. of employees
196
News stories
From web sources and news partners
FXLeaders
·
2 hours ago
Dow Jones and Nasdaq Futures Start Higher Ahead of US Inflation Data
CryptoRank
·
10 hours ago
Pokémon Cards Just Crushed Bitcoin, Gold and the S&P 500 With 150% Returns
Hindustan Times
·
6 hours ago
Why are 54% of US stocks down 20% as the S&P 500 nears a record high? | Hindustan Times
Traders Union
·
4 hours ago
Yuriy Matso: S&P500 negative beta to SPY at record 18.9 percent
Profile
Lakefront Biotherapeutics is a Belgian pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb.
The company develops drugs against rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis. Wikipedia
About Lakefront Biotherapeutics NV
CEOPaul Stoffels | Paul Stoffels
Employees196
Founded1999
Headquarters-
SectorBiotechnology
Websitelakefrontbio.com